<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00238784</url>
  </required_header>
  <id_info>
    <org_study_id>D5890L00004</org_study_id>
    <secondary_id>SOLO</secondary_id>
    <nct_id>NCT00238784</nct_id>
  </id_info>
  <brief_title>SOLO-Symbicort速 in the Treatment of Persistent Asthma in Adolescents &amp; Adults</brief_title>
  <official_title>A Comparison of Symbicort速 Single Inhaler Therapy (Symbicort速 200 Turbuhaler速 1 Inhalation b.i.d. Plus as Needed) &amp; Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents &amp; Adults-a 26-Week, Randomised, Open-Label, Parallel Group, Multicentre Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare Symbicort Single Inhaler treatment with the Best
      Conventional Practice in patients with persistent asthma
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first severe asthma exacerbation</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of asthma exacerbations</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean use of as-needed medication</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prescribed asthma medication</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported Outcomes</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care resource use</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Adverse Events, Serious Adverse Events and discontinuations due to Adverse Events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induced sputum will be sampled from a subset of patients</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All variables assessed over the 6 months treatment period</measure>
  </secondary_outcome>
  <enrollment>1300</enrollment>
  <condition>Asthma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide/formoterol Turbuhaler</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of asthma &lt; 3 months

          -  Prescribed daily use of glucocorticosteroids for at least 3 months prior to Visit 1

        Exclusion Criteria:

          -  Smoking history &gt; 10 pack-years

          -  Asthma exacerbation requiring change in asthma treatment during the last 14 days prior
             to inclusion

          -  Any significant disease or disorder that my jeopardize the safety of the patient.

        Additional inclusion and exclusion criteria will be evaluated by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca Rita Medical Science Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aldergrove</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bolton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.astrazeneca.com/node/emailtriage.aspx</url>
  </link>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2005</study_first_submitted>
  <study_first_submitted_qc>October 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2005</study_first_posted>
  <last_update_submitted>January 11, 2008</last_update_submitted>
  <last_update_submitted_qc>January 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

